Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/27726
Title: Multi-Modal Neuroimaging in Premanifest and Early Huntington's Disease: 18 Month Longitudinal Data from the IMAGE-HD Study.
Authors: Stout J.C.;Gray M.A.;Poudel G.R.;Churchyard A.;Chua P.;Georgiou-Karistianis N. ;Dominguez D J.F.;Egan G.F.
Institution: (Dominguez D, Egan, Gray, Poudel, Chua, Stout, Georgiou-Karistianis) School of Psychology and Psychiatry, Monash University, Clayton, VIC, Australia (Egan, Gray, Poudel) Monash Biomedical Imaging (MBI), Monash University, Melbourne, VIC, Australia (Egan, Poudel) Life Sciences Computation Centre, Victorian Life Sciences Computation Initiative (VLSCI), Melbourne, VIC, Australia (Egan) Centre for Neuroscience, University of Melbourne, Parkville, VIC, Australia (Gray) Centre for Advanced Imaging, Gehrmann Laboratory, The University of Queensland, St Lucia, QLD, Australia (Churchyard) Department of Neurology, Monash Medical Centre, Clayton, VIC, Australia
Issue Date: 3-Oct-2013
Copyright year: 2013
Publisher: Public Library of Science (185 Berry Street, Suite 1300, San Francisco CA 94107, United States)
Place of publication: United States
Publication information: PLoS ONE. 8 (9) (no pagination), 2013. Article Number: e74131. Date of Publication: 16 Sep 2013.
Abstract: IMAGE-HD is an Australian based multi-modal longitudinal magnetic resonance imaging (MRI) study in premanifest and early symptomatic Huntington's disease (pre-HD and symp-HD, respectively). In this investigation we sought to determine the sensitivity of imaging methods to detect macrostructural (volume) and microstructural (diffusivity) longitudinal change in HD. We used a 3T MRI scanner to acquire T1 and diffusion weighted images at baseline and 18 months in 31 pre-HD, 31 symp-HD and 29 controls. Volume was measured across the whole brain, and volume and diffusion measures were ascertained for caudate and putamen. We observed a range of significant volumetric and, for the first time, diffusion changes over 18 months in both pre-HD and symp-HD, relative to controls, detectable at the brain-wide level (volume change in grey and white matter) and in caudate and putamen (volume and diffusivity change). Importantly, longitudinal volume change in the caudate was the only measure that discriminated between groups across all stages of disease: far from diagnosis (>15 years), close to diagnosis (<15 years) and after diagnosis. Of the two diffusion metrics (mean diffusivity, MD; fractional anisotropy, FA), only longitudinal FA change was sensitive to group differences, but only after diagnosis. These findings further confirm caudate atrophy as one of the most sensitive and early biomarkers of neurodegeneration in HD. They also highlight that different tissue properties have varying schedules in their ability to discriminate between groups along disease progression and may therefore inform biomarker selection for future therapeutic interventions. © 2013 Dominguez D et al.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1371/journal.pone.0074131
PubMed URL: 24066104 [http://www.ncbi.nlm.nih.gov/pubmed/?term=24066104]
ISSN: 1932-6203 (electronic)
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/27726
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

12
checked on Sep 28, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.